Soleno reports positive Phase 3 results for DCCR in Prader-Willi; primary endpoint met (p=0.0022)

SOLENO THERAPEUTICS INC

Primary endpoint: HQ-CT total score difference of 5.0 at week 16 (p=0.0022) favoring DCCR over placebo.
Secondary endpoints (CGI-S, CGI-I) showed trends toward worsening in placebo group (p=0.08 and 0.09).
DCCR well-tolerated; no serious adverse events or discontinuations in DCCR group.
Positive data triggers $15M warrant exercise (8.6M shares at $1.75) within 30 days by Nantahala, Abingworth, Vivo.
Company targets NDA submission for DCCR in PWS mid-2024; FDA previously acknowledged potential for NDA support.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.